Publication date: December 2026 Source: The Breast, Volume 90 Author(s): A. de Nonneville, J.S. Frenel, D. Loirat, S. Becourt, N. Bénard, M.A. Benderra, M. Campone, F. Dalenc, O. Derbel, I. Desmoulins, A. Deleuze, G. Emile, A. Gonçalves, J. Grenier, W. Jacot, C. Liautard, L. Mansi, M.A. Mouret Reynier, C. Perkins, B. Pistilli
Real-world use of pembrolizumab in early-stage triple-negative breast cancer: Data from the French Early Access Program. // The Breast. – URL: https://www.sciencedirect.com/science/article/pii/S0960977626002584?dgcid=rss_sd_all
Real-world use of pembrolizumab in early-stage triple-negative breast cancer: Data from the French Early Access Program. The Breast. https://www.sciencedirect.com/science/article/pii/S0960977626002584?dgcid=rss_sd_all
“Real-world use of pembrolizumab in early-stage triple-negative breast cancer: Data from the French Early Access Program.” The Breast.
@article{article67635,
title = {Real-world use of pembrolizumab in early-stage triple-negative breast cancer: Data from the French Early Access Program},
journal = {The Breast},
url = {https://www.sciencedirect.com/science/article/pii/S0960977626002584?dgcid=rss_sd_all}
}